A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Nephrotic Syndrome
Interventions
DRUG

Mizoribine (MZR)

DRUG

Cyclophosphamide (CTX)

Trial Locations (28)

Unknown

Beijing Friendship Hospital, Capital Medical University, Beijing

Beijing Tongren Hospital, Capital Medical University, Beijing

China-Japan Friendship Hospital, Beijing

Chinese PLA General Hospital, Beijing

The Third Affiliated Hospital of the Third Military Medical University (Daping Hospital), Chongqing

Fuzhou General Hospital of Nanjing Military Region, Fuzhou

The first Affiliated Hospital of Fujian Medical University, Fuzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

Affiliated Hospital of Guilin Medical University, Guilin

The First Affiliated Hospital of Guangxi Medical University, Nanning

The Third Hospital of Hebei Medical University, Shijiazhuang

Wuxi People's Hospital, Wuxi

The First Affiliated Hospital of Nanchang University, Nanchang

The First Hospital of Jilin University, Changchun

The Second Hospital of Jilin University, Changchun

The First Affiliated Hospital of Dalian Medical University, Dalian

The General Hospital of Shenyang Military Region, Shenyang

Shandong Provincial Hospital, Jinan

The General Hospital of Jinan Military Region, Jinan

The Affilited Hospital of Qingdao University, Qingdao

Renji Hospital Shanghai Jiaotong University School of Medical, Shanghai

Xinhua Hospital Shanghai Jiaotong University School of Medical, Shanghai

Zhongshan Hospital Fudan University, Shanghai

The Second Hospital of Shanxi Medical University, Taiyuan

The First Affiliated Hospital of Xi'an Jiaotong University, Xian

West China Hospital of Sichuan University, Chengdu

Kuming General Hospital of Chengdu Military Region, Kunming

The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Asahi Kasei Pharma Corporation

INDUSTRY

NCT02257697 - A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome | Biotech Hunter | Biotech Hunter